drugset / Trial / NCT03916081
Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study will assess the safety, pharmacokinetics (PK), and efficacy of different doses of roflumilast (ARQ-151) cream (0.05% and 0.15%) vs placebo applied once daily (QD) for 28 days by adolescents and adults with atopic dermatitis.
Timeline
- Start
- 2019-05-31
- Primary completion
- 2019-11-04
- Completion
- 2019-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Roflumilast | Small molecule | 0.05 % | Topical |
| Comparator | Roflumilast | Small molecule | 0.15 % | Topical |